Dicer-Mediated Upregulation of BCRP Confers Tamoxifen Resistance in Human Breast Cancer Cells

Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas, USA.
Clinical Cancer Research (Impact Factor: 8.72). 08/2011; 17(20):6510-21. DOI: 10.1158/1078-0432.CCR-11-1403
Source: PubMed


Tamoxifen (Tam) is the most prescribed hormonal agent for treatment of estrogen receptor α (ERα)-positive breast cancer patients. Using microarray analysis, we observed that metastatic breast tumors resistant to Tam therapy had elevated levels of Dicer.
We overexpressed Dicer in ERα-positive MCF-7 human breast cancer cells and observed a concomitant increase in expression of the breast cancer resistance protein (BCRP). We thus hypothesized that Tam resistance associated with Dicer overexpression in ERα-positive breast cancer cells may involve BCRP. We analyzed BCRP function in Dicer-overexpressing cells using growth in soft agar and mammosphere formation and evaluated intracellular Tam efflux.
In the presence of Tam, Dicer-overexpressing cells formed resistant colonies in soft agar, and treatment with BCRP inhibitors restored Tam sensitivity. Tumor xenograft studies confirmed that Dicer-overexpressing cells were resistant to Tam in vivo. Tumors and distant metastases could be initiated with as few as five mammosphere cells from both vector and Dicer-overexpressing cells, indicating that the mammosphere assay selected for cells with enhanced tumor-initiating and metastatic capacity. Dicer-overexpressing cells with elevated levels of BCRP effluxed Tam more efficiently than control cells, and BCRP inhibitors were able to inhibit efflux.
Dicer-overexpressing breast cancer cells enriched for cells with enhanced BCRP function. We hypothesize that it is this population which may be involved in the emergence of Tam-resistant growth. BCRP may be a novel clinical target to restore Tam sensitivity.

Download full-text


Available from: Patrick Provost
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: MicroRNAs (miRNAs) have been reported to play a key role in oncogenesis. Genetic variations in miRNA processing genes and miRNA binding sites may affect the biogenesis of miRNA and the miRNA-mRNA interactions, hence promoting tumorigenesis. In the present study, we hypothesized that potentially functional polymorphisms in miRNA processing genes may contribute to head and neck cancer (HNC) susceptibility. To test this hypothesis, we genotyped three SNPs at miRNA binding sites of miRNA processing genes (rs1057035 in 3'UTR of DICER, rs3803012 in 3'UTR of RAN and rs10773771 in 3'UTR of HIWI) with a case-control study including 397 HNC cases and 900 controls matched by age and sex in Chinese. Although none of three SNPs was significantly associated with overall risk of HNC, rs1057035 in 3'UTR of DICER was associated with a significantly decreased risk of oral cancer (TC/CC vs. TT: adjusted OR  = 0.65, 95% CI  = 0.46-0.92). Furthermore, luciferase activity assay showed that rs1057035 variant C allele led to significantly lower expression levels as compared to the T allele, which may be due to the relatively high inhibition of hsa-miR-574-3p on DICER mRNA. These findings indicated that rs1057035 located at 3'UTR of DICER may contribute to the risk of oral cancer by affecting the binding of miRNAs to DICER. Large-scale and well-designed studies are warranted to validate our findings.
    Full-text · Article · Oct 2012 · PLoS ONE
  • [Show abstract] [Hide abstract]
    ABSTRACT: The resistance of cancerous cells to chemotherapeutic agents is an important issue in the treatment of breast cancer. Although estrogens and xenoestrogens have been implicated in the tumorigenesis of breast cancer, their roles in chemoresistance are not clear. These compounds can activate classical estrogen receptors as well as other types of receptors, such as aryl hydrocarbon receptor. Through the ligand–receptors activation, they control the target genes and signaling pathways. Herein, we review evidence that estrogens and xenoestrogens antagonize multiple anticancer drugs by antiapoptosis, drug efflux, and promoted proliferation. In addition, novel therapeutic targets of breast cancer have been proposed from these signaling pathways, such as ceramide/sphingosine 1-phosphate. A better understanding of the mechanisms of chemoresistance induced by estrogen or xenoestrogen could provide important insights into the strategy for breast cancer treatment.
    No preview · Article · Dec 2012 · Journal of Experimental and Clinical Medicine
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent understanding of oncogene regulation has uncovered anemerging new field of molecular cancer biology in which tumorsuppressors and mediators are controlled through RNA regulation.Among the most critical players are microRNA (miRNA), also referred toas 'oncomirs', and Dicer, the major enzyme responsible for cleavingdouble-stranded RNA and forming the RNA induced silencing complex.These components are aberrantly expressed in cancer and among sometumor types are hypothesized to be causative to the etiology ofmalignancy. For example, prostate and colorectal cancers expressabundantly high levels of Dicer mRNA while lung, ovarian and endometrial cancers express low levels of Dicer, which is believed tocorrelate to poor cancer prognosis. In addition, mutations of the Dicerencoding gene (DICER1) occur in non-epithelial ovarian cancers andpediatric tumor pleuropulmonary blastoma. Paradoxically, Dicer is ahaploinsufficient tumor suppressor; the loss of a single allele of DICER1enhances tumor growth where the loss of the second allele results inhalting tumor proliferation. MicroRNA regulates oncogenic signalingpathways as well as the expression of tumor suppressors and oncogenes,making it a major contributor to the overall status of the cell and itsmalignant potential. The let-7 miRNA family members are well-known astumor suppressor genes, which target and silence the Ras oncogene. Onthe other hand, miRNAs may induce tumor growth; one example is miR-17-19 cluster negatively regulating two tumor suppressor genes, PTENand Bim. In this chapter, the regulation of oncomirs will be discussedwith focus on the post-transcriptional control by miRNA biogenesismachinery, which consist Dicer as a major player.
    No preview · Article · Jan 2013
Show more